GlassScriptPhysician profile
David Anthony De Rose
NPI 1255443073
$58,107.29
in general payments reported to CMS, 2019-2025
26 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $230 · 2021: $6,120 · 2022: $21K · 2023: $12K · 2024: $2,383 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,113 · Travel and Lodging: $3,653 · Food and Beverage: $2,890 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,525.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,113.00 |
| Travel and Lodging | $3,652.58 |
| Food and Beverage | $2,889.65 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $45,886.82 | 2020-2025 | Argos, Clareon, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $6,000.00 | 2025 | |
| Alcon Research LLC | $1,400.00 | 2022 | |
| Allergan, INC. | $1,280.79 | 2019-2022 | |
| Abbvie INC. | $545.83 | 2022-2025 | Lumigan |
| Rxsight INC | $540.90 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Biotissue Holdings INC. | $520.79 | 2022-2025 | |
| Ivantis, INC | $347.34 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $253.28 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $141.23 | 2019-2020 | |
| Glaukos Corporation | $128.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $124.80 | 2019 | |
| Kala Pharmaceuticals, INC. | $124.80 | 2019 | |
| Genentech USA, INC. | $124.80 | 2019 | |
| Eyevance Pharmaceuticals LLC | $124.80 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $117.93 | 2025 | |
| Dompe US, INC. | $103.62 | 2019 | |
| Sight Sciences, INC. | $72.71 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec, INC. | $64.71 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $43.18 | 2024 | |
| Sun Pharmaceutical Industries INC. | $42.35 | 2023-2025 | Cequa |
| Medtronic, INC. | $32.79 | 2024 | Linq II |
| Harrow Eye, LLC | $25.90 | 2025 | Vevye |
| Ocular Therapeutix, INC. | $22.53 | 2024 | Dextenza |
| Beaver-Visitec International, INC. | $18.92 | 2021 | |
| Quidel Corporation | $17.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David De Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.